Clinical translation of 177Lu-labeled PSMA-617: Initial experience in prostate cancer patients

Nuclear Medicine and Biology

Volumn 43, Issue 5, 2016, Pages 296-302

  Das, Tapas ^a,b   Guleria, Mohini ^a   Parab, Anil ^c   Kale, Chanchala ^c   Shah, Hina ^c   Sarma, Haladhar D ^a   Lele, Vikram R ^c   Banerjee, Sharmila ^a,b  

^a BHABHA ATOMIC RESEARCH CENTRE   (India)

^b HOMI BHABHA NATIONAL INSTITUTE   (India)

^c JASLOK HOSPITAL AND RESEARCH CENTRE   (India)

Author keywords

177Lu; Prostate cancer; PSMA 617; Targeted radionuclide therapy; Theranostic application

Indexed keywords

PROSTATE SPECIFIC MEMBRANE ANTIGEN 617 LU 177; RADIOISOTOPE; UNCLASSIFIED DRUG; DIPEPTIDE; LUTETIUM; PSMA-617; SINGLE HETEROCYCLIC RINGS;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG STABILITY; DRUG UPTAKE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; MALE; NONHUMAN; PROSTATE CANCER; RADIOCHEMISTRY; RADIOISOTOPE THERAPY; RAT; ANIMAL; CHEMISTRY; DIAGNOSTIC IMAGING; METABOLISM; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; PROSTATIC NEOPLASMS; RADIATION DOSE; TISSUE DISTRIBUTION; TRANSLATIONAL RESEARCH; TUMOR CELL LINE; WISTAR RAT;

ANIMALS; CELL LINE, TUMOR; DIPEPTIDES; DRUG STABILITY; HETEROCYCLIC COMPOUNDS, 1-RING; HUMANS; LUTETIUM; MALE; POSITRON-EMISSION TOMOGRAPHY; PROSTATIC NEOPLASMS; RADIATION DOSAGE; RATS; RATS, WISTAR; TISSUE DISTRIBUTION; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84961840033     PISSN: 09698051     EISSN: 18729614     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2016.02.002     Document Type: Article

References (30)

1. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J Clin 2011, 61:69-90.
2. 68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur J Nucl Med Mol Imaging 2013, 40:486-495.
3. Ahkhtar N.H., Orrin P., Saran A., Tyrell L., Tagawa S.T. Prostate-specific membrane antigen-based therapeutics. Adv Urol 2012, 10.1155/2012/973820.
4. Mannweiler S., Amersdorfer P., Trajanoski S., Terrett J., King D., Mehes G. Heterogeneity of prostate-specific membrane antigen (PSMA) expression in prostate carcinoma with distant metastasis. Pathol Oncol Res 2009, 15:167-172.
5. Benešová M., Schäfer M., Bauder-Wüst U., Afshar-Oromieh A., Kratochwil C., Mier W., et al. Preclinical evaluation of a tailor-made DOTA-conjugated PSMA inhibitor with optimized linker moiety for imaging and endoradiotherapy of prostate cancer. J Nucl Med 2015, 56:914-920.
6. Bostwick D.G., Pacelli A., Blute M., Roche P., Murphy G.P. Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases. Cancer 1998, 82:2256-2261.
7. Barrett J.A., Coleman R.E., Goldsmith S.J., Vallabhajosula S., Petry N.A., Cho S., et al. First-in-man evaluation of 2 high-affinity PSMA-avid small molecules for imaging prostate cancer. J Nucl Med 2013, 54:380-387.
8. Maresca K.P., Hillier S.M., Femia F.J., Keith D., Barone C., Joyal J.L., et al. A series of halogenated heterodimeric inhibitors of prostate specific membrane antigen (PSMA) as radiolabeled probes for targeting prostate cancer. J Med Chem 2009, 52:347-357.
9. 99mTc-labeled small-molecule inhibitors of prostate-specific membrane antigen for molecular imaging of prostate cancer. J Nucl Med 2013, 54:1369-1376.
10. 99mTc-labeled imaging agents for the prostate-specific membrane antigen (PSMA). J Med Chem 2013, 56:6108-6121.
11. 18FDCFBC, a low-molecular-weight inhibitor of prostate-specific membrane antigen, in patients with metastatic prostate cancer. J Nucl Med 2012, 53:1883-1891.
12. 68Ga-Complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging. Bioconjug Chem 2012, 23:688-697.
13. Afshar-Oromieh A., Hetzheim H., Kratochwil C., Benesova M., Eder M., Oliver C., et al. The novel theranostic PSMA ligand PSMA-617 in the diagnosis of prostate cancer by PET/CT: biodistribution in humans, radiation dosimetry and first evaluation of tumor lesions. J Nucl Med 2015, 56:1697-1705.
14. Banerjee S., Pillai M.R.A., Knapp F.F. Lutetium-177 therapeutic radiopharmaceuticals: linking chemistry, radiochemistry and practical applications. Chem Rev 2015, 115:2934-2974.
15. 177Lu-DOTATATE therapy in patients with neuroendocrine tumours: 5 years' experience from a tertiary cancer care centre in India. Eur J Nucl Med Mol Imaging 2014, 41:1319-1326.
16. 177Lu-EDTMP for palliation of pain from bone metastases in patients with prostate and breast cancer: a phase II study. Eur J Nucl Med Mol Imaging 2015, 42:79-88.
17. 153Sm-EDTMP on equidose basis. J Nucl Med 2015, 56:1513-1519.
18. Novaković B.J., Kotnik V., Šetina T.J., Vovk M., Novaković S. Testing of mechanisms of action of rituximab and clinical results in high-risk patients with aggressive CD20+ Lymphoma. Radiol Oncol 2007, 41:23-32.
19. 177Lu-labeled hydroxyapatite particulates: first human study and initial Indian experience. World J Nucl Med 2015, 14:81-88.
20. 177Lu for radionuclide therapy. Appl Radiat Isot 2003, 59:109-118.
21. Das T., Pillai M.R.A. Options to meet the future global demand of radionuclides for radionuclide therapy. Nucl Med Biol 2013, 40:23-32.
22. Das T., Banerjee S. Theranostic applications of Lutetium-177 in radionuclide therapy. Curr Radiopharm 2016, 9:94-101.
23. 177Lu]Lutetium-labelled PSMA ligand-induced remission in a patient with metastatic prostate cancer. Eur J Nucl Med Mol Imaging 2015, 42:987-988.
24. 177Lu-PSMA is set to redefine prostate cancer treatment. Curr Radiopharm 2016, 9:6-7.
25. Lütje S., Heskamp S., Cornelissen A.S., Poeppel T.D., van den Broek S.A.M.W., Rosenbaum-Krumme S. PSMA ligands for radionuclide imaging and therapy of prostate cancer: clinical status. Theranostics 2015, 5:1388-1401.
26. 18F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging 2014, 41:11-20.
27. 68Ga-labelled PSMA ligand for the diagnosis of recurrent prostate cancer: initial experience. Eur J Nucl Med Mol Imaging 2014, 41:887-897.
28. Baum R.P., Wahl R.L. Third Theranostics World Congress on Gallium-68 and PRRT: Abstracts. J Nucl Med 2015, 56(Suppl. 2):2A-30.
29. Baum R.P., Kulkarni H.R., Schuchardt C., Singh A., Wirtz M., Wiessalla S., et al. Lutetium-177 PSMA radioligand therapy of metastatic castration-resistant prostate cancer: Safety and efficacy. J Nucl Med 2016, 10.2967/jnumed.115.168443.
30. 177Lu-PSMA-617 prostate-specific membrane antigen (PSMA) inhibitor in patients with castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging 2015, 42:1976-1983.